期刊文献+

唑来膦酸致下颌骨疼痛一例 被引量:1

下载PDF
导出
摘要 患者男,39岁,因右肺占位入院。体格检查:右颈部可触及大小约2 cm×2 cm 肿大淋巴结,质硬,与周围粘连,活动度差,未诉压痛。心肺腹及神经系统查体无明显异常。辅助检查:入院后行右颈部淋巴结活检送检,病理回报肺腺癌。查骨发射单光子计算机断层扫描仪(ECT)提示腰椎浓聚,查椎体磁共振成像(MRI)示腰4椎体骨转移。应用唑来膦酸4 mg 缓慢静脉滴注后,出现颞颌关节疼痛,伴双膝关节疼痛。查体:体温38℃,余未见异常。血常规检查:白细胞43×109/L,中性粒细胞60%。给予布洛芬缓释胶囊03 g ,口服2 h 后,患者症状逐渐消失。第2周期返院后患者再次应用唑来膦酸静脉滴注,又出现颞颌关节、双膝关节疼痛,伴发热。查体:体温382℃。仔细追问病史,用药前未有上述症状,考虑为唑来膦酸所致,即停药,再次给予布洛芬缓释胶囊03 g,口服,症状逐渐消失。
出处 《山西医药杂志》 CAS 2014年第7期845-845,共1页 Shanxi Medical Journal
  • 相关文献

参考文献5

  • 1Ruggiero SL, Mehrotra ]3, Rosenberg TJ, et al. Osteoneero- sis of the jaws associated with the use of bisphosphonates: a review of 63 cases [-J 1. J Oral Maxillofac Surg, 2004,62 (5) : 527-534.
  • 2秦燕,冯奉仪.帕米膦酸二钠和唑来膦酸的临床适应证及相关毒性[J].癌症进展,2008,6(1):16-20. 被引量:19
  • 3黄建权,傅得兴,孙春华.双膦酸盐类药物不良反应及应用评价[J].中国医院用药评价与分析,2008,8(5):325-327. 被引量:13
  • 4Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis[J]. Ther Clin Risk Manag, 2006,2(1) :77-86.
  • 5Ferretti G, Fabi A, Car]ini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metallo- proteinases and proinflammatory cytokines in metastatic breast cancer patientsl-J]. Oncology, 2005,69 (1) : 35-43.

二级参考文献48

  • 1[1]Hortobagyi GN,Theriault RL,Lipton A,et al.Longerm prevention of skeletal complications of metastatic breast cancer with pamidronate.J Clin Oncol,1998,16:2038
  • 2[2]Theriault RL,Lipton A,Hortobagyi GN,et al.Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:A randomized,placebo-controlled trial.Protocol 18 Aredia Breast Cancer Study Group.J Clin Oncol,1999,17:846
  • 3[3]Conte PF,Latreille J,Mauriac L,et al.Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate:Results from a multinational randomized controlled trial.J Clin Oncol,1996,14:2552
  • 4[4]Berenson JR,Lichtenstein A,Porter L,et al.Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events.Myeloma Aredia Study Group.J Clin Oncol,1998,16:593
  • 5[5]Rosen LS,Gordon D,Kaminski M,et al.Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma:A randomized,double-blind,multicenter,comparative trial.Cancer,2003,98:1735
  • 6[6]Saad F,Gleason D,Murray R,et al.A randomized,placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.J Natl Cancer Inst,2002,94:1458
  • 7[7]Small EJ,Smith MR,Seaman JJ,et al.Combined analysis of two multicenter,randomized,placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.J Clin Oncol,2003,21:4277
  • 8[8]Saad F,Gleason DM,Murray R,et al.Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.J Natl Cancer Inst,2004,96:879
  • 9[9]Major P,Lortholary A,Hon J,et al.Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:A pooled analysis of two randomized,controlled clinical trials.J Clin Oncol,2001,19:558
  • 10[10]Lacy MQ,Dispenzieri A,Gertz MA,et al.Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.Mayo Clin Proc,2006,81:1047

共引文献30

同被引文献24

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部